scientific program • symposia - American Society for Reproductive ...

SCIENTIFIC PROGRAM • SYMPOSIA
Monday, October 17, 2011 11:15 am – 1:00 pm
Symposium
Room 222
BUSINESS DEVELOPMENT IN AN UNCERTAIN MARKET
Presented by the Assisted Reproductive Managers
Rita Gruber, B.A. (Chair)
Reproductive Medicine Associates of New Jersey
Lisa A. Rinehart, R.N, B.S.N., J.D.
Reproductive Medicine Institute, Illinois
Joseph J. Travia, B.A., M.B.A., C.P.A.
IntegraMed
Needs Assessment and Description
With the global economic meltdown in 2008 and 2009
along with the current fiscal crisis around the world, how are
practices in reproductive endocrinology and fertility going
to be able to survive and prosper during this difficult time. In
the age of social media and rapidly changing technology
what can practices do to meet the challenges and
opportunities in a new world order focused on the patient
experience?
REI specialists and their staff must work to become the
destination of choice for patients in their market. The
patient assumes that your practice is medically and
clinically solid – this is a given. However the patient is
looking for and demanding a practice that focuses on the
patient experience from the moment of first contact to
the convenience of office locations, the day-to-day staff
interactions and the handling of the final bill. Discussions will
include all facets of the patient experience, from referring
physicians, education and payers up to and including
their final visit with the fertility center. The components of a
Monday, October 17, 2011 1:00 pm – 2:30 pm
Menopause Day Luncheon Symposium (Ticketed)
TODAY’S APPROACHES TO TREATING THE MENOPAUSE:
RISKS AND BENEFITS OF VARIOUS THERAPIES
Cynthia K. Sites, M.D.
Tufts University
Lubna Pal, M.B.B.S., M.S.
Yale University
Genevieve Neal-Perry, M.D., Ph.D.
Albert Einstein College of Medicine
Needs Assessment and Description
Women and their health care providers are increasingly
confused as to the actual risks/benefits of therapeutic
options available to treat menopausal symptoms and
osteoporosis. Women continue to seek reliable information
while also exploring alternative therapies. Despite
considering healthcare providers the most reliable source
of information, women expressed low confidence in their
provider’s ability to give sufficient information and to
describe alternative therapies. Large gaps exist between
patient expectations and provider preparedness to guide
patient decision making. Selective estrogen reuptake
modulators (SERMs), bisphosphonates, teriparatide,
calcitonin and denosumab are recognized alternatives
to hormone therapy for the treatment of osteoporosis.
Tissue selective estrogen complexes (TSECs) that exhibit
tissue specific estrogen agonist/antagonist activity are
emerging as a promising alternative to traditional hormone
therapy for the treatment of menopausal osteoporosis.
For menopausal hot flash symptoms, treatments such as
gabapentin, selective serotonin reuptake inhibitors (SSRIs),
and selective norepinephrine reuptake inhibitors (SNRIs)
are considered alternatives to hormone therapy, and
TSECs again represent an emerging option for managing
Valencia Ballroom
Supported by an independent educational grant from Pfizer.
66
strategic plan will also be discussed with a focus on practice
development.
Learning Objectives
At the conclusion of this session, participants should be able
to:
1. Identify several external factors that drive the current
models of fertility practices.
2. Develop a comprehensive plan focused on the patient
experience.
3. Discuss a framework for strategic planning at a fertility
center.
ACGME COMPETENCY
Systems-Based Practice
TEST QUESTION:
REI practices are becoming increasingly aware that
outstanding medical and clinical care is not enough to
operate a financially successful fertility practice. Designing
a practice around the patient experience and utilizing the
tools available to help you exceed their expectations is
paramount during these difficult times. After participating
in this session, in my practice I will develop a Strategic Plan
that includes each of the following except:
A. Executive Summary
B. Marketing Plan
C. Financial Projections
D. Number of members in AARP by state
E. SART Data
menopausal vaginal atrophy. The decision to use any
therapy depends on a patient’s clinical presentation and
a thorough evaluation of the risks and benefits. In a survey
conducted by ASRM in 2009 and 2011, members identified
personal practice gaps involving the treatment of various
menopausal symptoms and osteoporosis. Physicians
requested educational activities to specifically address their
understanding of individualized treatment approaches.
Learning Objectives
At the conclusion of this session, participants should be able
to:
1. Compare and contrast estrogen therapies versus mixed
agonist/antagonist treatment therapies (SERMs and tissue
selective estrogen complexes,TSECs) in treating
menopausal symptoms
2. Discuss the efficacy, risks, and benefits of mixed agonist/
antagonist agents in the treatment of menopausal
osteoporosis
3. Design treatment plans for women of different ages with
menopausal symptoms
ACGME COMPETENCY
Medical Knowledge
Patient Care
TEST QUESTION:
After participating in this session, in my practice I will:
A. Prescribe denosumab for perimenopausal women diagnosed
with osteopenia.
B. Prescribe parathyroid hormone to women deemed at high risk for
fracture.
C. Prescribe TSECs for control of vasomotor symptoms.
D. Prescribe SERMs for symptomatic women at risk for fracture.
E. Not applicable to my area of practice.